Discover Viatris

Mylan is now part of Viatris, a new global healthcare company committed to empowering people to live healthier at every stage of life.

Although this Mylan site remains active for now, we encourage you to visit the Viatris site to learn more about our commitment to increasing access to quality medicines for patients when and where they need them.

Oct 19, 2015

Women may be suffering needlessly during menopause

Women may be suffering needlessly during menopause

London, October 19, 2015 – Menopause is so distressing it leaves a fifth of women feeling 'depressed'i and almost half suffering from low mood or mood changesii, a new survey* reveals.

Women need support when facing menopause

The survey, commissioned by Mylan, questioned 1,013 women aged between 40 and 60 who have gone through or are going through the menopause. The results show that the menopause can 'significantly' impair the lives of women on a daily basisiii. 45 per cent described themselves as ‘tired’iv, and over a third (39 per cent) experienced memory and concentration lossv

Yet they could be suffering needlessly. A staggering 85 per cent of women are avoiding hormone replacement therapy (HRT)vi which could alleviate the most common daily symptoms associated with the menopause. 

The menopause, in which a woman's menstrual period stops permanently, leaves 4 in 10 (41 per cent) struggling to sleepvii, and just 1 in 5 enjoy their sexuality more in middle age than they did in their youthviii

Psychologist Susan Quilliam states, “Women in their fifties are the original Baby Boomer generation who led the sexual revolution. We are now seeing a record number of divorces with an increasing number of women in this age group returning to dating, so it’s a shame that just 1 in 6 has a better sex life now than they did in their twentiesix, with just one in three maintaining their ‘lust for life’x.” 

NICE Guidelines: women should receive better support and information on menopause treatment solutions

In November, NICE (National Institute for Health and Care Excellence) will issue new guidelines in diagnosis and management of the menopause, which are the first guidelines in the EU within the therapy area in over 10 years. For the first time, the guidance will provide advice to women to help them make informed treatment choices based on their individual symptoms and needs. 

Susan Quilliam adds, “Women can experience vastly differing symptoms throughout the menopause, however collectively they now have the unique opportunity to lead a new intimacy revolution, redefining what it means to be menopausal, just as they have redefined every stage of life as they have lived it.

Women need to equip themselves with information on tailored treatment options to ensure they are getting the best support, so they can maintain their lust for life.”

Leading GP and women’s health specialist, Dr. Sarah Gray states, “The results show that menopausal women are currently reluctant to seek help for their daily symptoms due to confusion over the role and safety of HRT; over 1 in 4 told us that they avoided HRT over safety fears, and nearly 1 in 6 said they were unsure whether HRT would benefit themxi. This means that many women may be unnecessarily experiencing symptoms that are impairing their quality of life on a daily basis.” 

The survey identified hot flushes (72 per cent) and sweats (60 per cent) as the most common symptomsxii, both of which can be alleviated with tailored HRT treatment. 

Dr. Sarah Gray adds, “Many studies show that HRT can help improve women’s lives, offering both long and short term benefits. As well as combatting short term symptoms like hot flushes and night sweats, HRT also offers protection against osteoporosis, helping to avoid the scourge of fracture, pain and loss of independence. Women need to know about the available options, their risks and benefits and be empowered to become part of the decision-making process.” 

In the past, many menopausal women with low moods have turned to anti-depressants or anxiety medication, when an effective alternative might be HRT, so it’s important that women explore all the options available.” 

Julian De Gabriele, Mylan U.K. Head of Medical Affairs, comments, “The new guidelines will inform and reassure women who are seeking a solution for their menopausal symptoms. We urge women to explore their treatment options, which should be tailored to individual symptoms and needs, so that they have more control over how they feel during the menopause, and can enjoy life without limits.”


About Mylan
Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, w—e innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of around 1,400 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which nearly 50% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in about 145 countries and territories. Our workforce of approximately 30,000 people is dedicated to creating better health for a better world, one person at a time. Learn more at

Notes to Editors

For further information or comment, please contact:
Rosie Harrold: / 020 7067 0821
Shelley George: / 020 7067 0337
Mary Hinks-Edwards: / 020 7067 0180

* Mylan survey conducted by Censuswide, October 2015

i Mylan survey conducted by Censuswide, October 2015 (Q6a)
ii Mylan survey conducted by Censuswide, October 2015 (Q1)
iii Mylan survey conducted by Censuswide, October 2015 (Q4) - 37% answered ‘somewhat’; 7% answered ‘significantly’
iv Mylan survey conducted by Censuswide, October 2015 (Q6a)
v Mylan survey conducted by Censuswide, October 2015 (Q1)
vi Mylan survey conducted by Censuswide, October 2015 (Q2a)
vii Mylan survey conducted by Censuswide, October 2015 (Q10)
viii Mylan survey conducted by Censuswide, October 2015 (Q5b)
ix Mylan survey conducted by Censuswide, October 2015 (Q5b)
x Mylan survey conducted by Censuswide, October 2015 (Q5a)
xi Mylan survey conducted by Censuswide, October 2015 (Q2c)
xii Mylan survey conducted by Censuswide, October 2015 (Q1)

Last Updated  04/08/2017